预约演示

Boehringer and Kyowa Kirin sign fibro-inflammatory treatment deal

2024-01-08

交易

引进/卖出免疫疗法临床3期

Boehringer Ingelheim intends to create breakthrough therapies’to enhance patient outcomes. Credit: Boehringer Ingelheim International.

Boehringer Ingelheim has signed a licensing agreement with Japan’s Kyowa Kirin to develop a new treBoehringer Ingelheim Internationalases.

Boehringer Ingelheim Boehringer Ingelheim’s strategy to create breaKyowa Kirinerapies in this disease area to fibro-inflammatory diseases

Boehringer Ingelheim Boehringer Ingelheimve rights from the Japanese pharmaceutical and biotechnology company to develop treatments globally.

Boehringer Ingelheimeive €410m, including an upfront payment and additional success-based milestones, along with sales royalties.

Kyowa Kirin senior managing executive officer, chief medical officer and board director Takeyoshi Yamashita stated: “We are pleased to announce that we have signed the licence agreement with Boehringer Ingelheim.

“The compound was discovered through Kyowa Kirin’s expertise in innovative technology and disease biology. Boehringer Ingelheim is highly regarded for its expertise in fibro-inflammatory diseBoehringer Ingelheim that it should be the best partner to maximise and deliver the value of our compound for patients in need.”

Fibro-inflammatory diseases, which inKyowa Kirintions such as systemic sclerosis and lung fibrosis, are cauBoehringer Ingelheimmmation and are a significant source of mfibro-inflammatory diseasesally.

Fibro-inflammatory diseasesct a patient’s quality of life and systemic sclerosisr morlung fibrosisird of deaths wochronic inflammation

Boehringer Ingelheim corporate senior vice-president and discovery research global head Clive Wood stated: “We are very excited about partnering with Kyowa Kirin and being able to add this opportunity to our portfolio to develop breakthrough treatments for patients with this new collaboration.”

Boehringer Ingelheimting Phase III clinical trials for BI 1015550, a PDE4B inhibitor, targeting idiopathic pulmonary fibrosis and other progressive fiKyowa Kirinerstitial lung diseases.